Cannabidiol Oral Solution for the Treatment of Patients With Prader-Willi Syndrome

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-09

Study Completion Date

2019-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to assess the efficacy of cannabidiol oral solution on hyperphagia-related behavior in patients with Prader-Willi Syndrome (PWS). The secondary objectives of this study are to assess the efficacy, safety and tolerability, impact on quality of life, and impact on physical activity of cannabidiol oral solution in patients with PWS.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)

NCT03848481

Prader-Willi Syndrome

COMPLETED PHASE2

Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome

NCT02318563

Dravet Syndrome

WITHDRAWN PHASE3

Cannabidiol Oral Solution for Treatment of Refractory Infantile Spasms

NCT02551731

Spasms, Infantile

TERMINATED PHASE2

A Phase 2 Study of Radiprodil in Subjects With Drug-resistant Infantile Spasms (IS)

NCT02829827

Infantile Spasms (IS)

TERMINATED PHASE2

NB-001 in Children and Adolescents With 22q11 Deletion Syndrome

NCT05290493

22q11 Deletion Syndrome

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prader-Willi Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cannabidiol

Cannabidiol oral solution (40 milligram/kilogram/day \[40 mg/kg/day\]) divided into two daily doses with a standard meal

Group Type EXPERIMENTAL

Cannabidiol

Intervention Type DRUG

Oral solution

Placebo

Matching placebo solution divided into two daily doses with a standard meal

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Matching oral solution

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cannabidiol

Oral solution

Intervention Type DRUG

Placebo

Matching oral solution

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant and/or parent(s)/caregiver(s) fully comprehend the informed consent form and assent form, understand all study procedures, and can communicate satisfactorily with the investigator and study coordinator, in accordance with applicable laws, regulations, and local requirements.
* Participants with a genetically confirmed diagnosis of Prader-Willi Syndrome using standard deoxyribonucleic acid methylation test or fluorescent in situ hybridization. Documentation of genetically confirmed diagnosis of Prader-Willi Syndrome is acceptable.
* A score of ≥10 on the Hyperphagia Questionnaire for Clinical Trials (HQ-CT).
* A caregiver is available to complete the HQ-CT.
* If female, is either not of childbearing potential (defined as premenarchal or surgically sterile \[bilateral tubal ligation, bilateral oophorectomy, or hysterectomy\]) or practicing one of the following medically acceptable methods of birth control:

1. Hormonal methods such as oral, implantable, injectable, vaginal ring, or transdermal contraceptives for a minimum of 1 full cycle (based on the participant's usual menstrual cycle period) before study drug administration.
2. Total abstinence from sexual intercourse since the last menses before study drug administration.
3. Intrauterine device.
4. Double-barrier method (condoms, sponge, or diaphragm with spermicidal jellies or cream).
* Adequate renal function, defined as serum creatinine ≤ 1.5\*upper limit of normal (ULN) and urine protein/creatinine ratio ≤0.4. The Investigator may deem the participant eligible if he or she judges the laboratory values to be not clinically significant.
* Adequate hepatic function, defined as total bilirubin ≤ 1.5\*ULN and aspartate aminotransferase and alanine aminotransferase levels ≤ 3\*ULN.
* Growth hormone treatment will be permitted if doses have been stable for at least 1 month prior to screening.
* Psychotropic treatment will be permitted and should be stable at least 6 weeks prior to screening.
* Any other treatment including thyroid hormones should be stable for at least 6 weeks prior to screening.

Exclusion Criteria

* Known use of cannabis or cannabinoid-containing products for 4 weeks prior to baseline.
* History of chronic liver diseases, such as cirrhosis or chronic hepatitis due to any cause, or suspected alcohol abuse.
* Use of weight loss agents or drugs known to affect appetite (including glucagon-like peptide-1 \[GLP-1\] analogs) within 2 months prior to screening.
* Uncontrolled Type I and Type II diabetes.
* Currently taking concomitant medication that are strong-moderate inhibitors/inducers/sensitive substrates with a narrow therapeutic index for CYP2C19 or CYP3A.
* Co-morbid condition or disease (such as respiratory disease, heart disease, or psychiatric disorder) diagnosed less than 1 month prior to screening.
* History or presence of gastrointestinal or any other condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs as determined by the Investigator.
* Participants who have participated in any other trials involving an investigational product or device within 30 days of screening or longer as required by local regulations.
* Clinically significant abnormalities on electrocardiogram at screening or other evidence of heart disease as determined by the Investigator.
* Has screening systolic blood pressure ≥160 millimeters of mercury (mmHg) and diastolic blood pressure \>100 mm Hg (may be repeated 1 additional time after 5 minutes rest to verify). Participants with hypertensive levels lower than those specified may be excluded at the Investigator's discretion if deemed to be in the best interest of the participant.
* Currently taking felbamate.
* Uncontrolled sleep apnea.
* Pregnant or lactating female.
* History of hypersensitivity to drugs with a similar chemical structure or class as cannabidiol.
* Unwillingness or inability to follow the procedures outlined in the protocol.
* Participant judged by the investigator or sponsor (or designee) as unable to comply with the treatment protocol, including appropriate supportive care, follow-up and research tests.
* Positive drug screen, including tetrahydrocannabinol, at time of screening.
* Creatinine clearance test of \< 30 milliliters/minute (mL/min).

Minimum Eligible Age

8 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No